Scholarlink

<p><i>Pseudomonas aeruginosa</i> (<i>P. aeruginosa)</i> is a major opportunistic pathogen with strong biofilm-forming ability and high resistance to antibiotics. Natural flavonoids such as rutin and luteolin possess antimicrobial potential, but their poor solubility and bioavailability limit therapeutic applications. This study evaluated the antibacterial and anti-biofilm efficacy of rutin–luteolin encapsulated chitosan nanoparticles (RUT-LUT-CS) against clinical and reference strains of <i>P. aeruginosa</i>. RUT-LUT-CS nanoparticles were spherical with an average size of 285&#xa0;nm (FESEM), hydrodynamic diameter of 470&#xa0;nm (DLS), and a positive zeta potential of + 31.8 mV. Antimicrobial susceptibility assays showed that RUT-LUT-CS reduced MIC and MBC values four-fold (0.78 and 1.56&#xa0;mg/mL) compared to free RUT-LUT (3.125 and 6.25&#xa0;mg/mL). Agar-well diffusion demonstrated inhibition zones of 22–29&#xa0;mm for RUT-LUT-CS versus 15–23&#xa0;mm for free compounds. Biofilm assays revealed that RUT-LUT-CS inhibited biofilm formation by &gt; 70%, reducing activity from strong to poor categories in all isolates, while free RUT-LUT achieved only ~ 40–50% inhibition. Gene expression analysis further confirmed significant downregulation, with <i>pelA</i> reduced by 70–80% and <i>rhlR</i> by 55–65% relative to untreated controls. RUT-LUT-CS nanoparticles exhibit superior antimicrobial and anti-biofilm activities compared with free flavonoids, suggesting strong potential as an effective therapeutic strategy against multidrug-resistant <i>P. aeruginosa</i>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rutin-luteolin flavonoid-encapsulated chitosan nanoparticles: a novel strategy to combat multidrug-resistant Pseudomonas aeruginosa

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月6日

查看全文
  • Helia Ramezani,
  • Hossein Sazegar,
  • Leila Rouhi

摘要

Pseudomonas aeruginosa (P. aeruginosa) is a major opportunistic pathogen with strong biofilm-forming ability and high resistance to antibiotics. Natural flavonoids such as rutin and luteolin possess antimicrobial potential, but their poor solubility and bioavailability limit therapeutic applications. This study evaluated the antibacterial and anti-biofilm efficacy of rutin–luteolin encapsulated chitosan nanoparticles (RUT-LUT-CS) against clinical and reference strains of P. aeruginosa. RUT-LUT-CS nanoparticles were spherical with an average size of 285 nm (FESEM), hydrodynamic diameter of 470 nm (DLS), and a positive zeta potential of + 31.8 mV. Antimicrobial susceptibility assays showed that RUT-LUT-CS reduced MIC and MBC values four-fold (0.78 and 1.56 mg/mL) compared to free RUT-LUT (3.125 and 6.25 mg/mL). Agar-well diffusion demonstrated inhibition zones of 22–29 mm for RUT-LUT-CS versus 15–23 mm for free compounds. Biofilm assays revealed that RUT-LUT-CS inhibited biofilm formation by > 70%, reducing activity from strong to poor categories in all isolates, while free RUT-LUT achieved only ~ 40–50% inhibition. Gene expression analysis further confirmed significant downregulation, with pelA reduced by 70–80% and rhlR by 55–65% relative to untreated controls. RUT-LUT-CS nanoparticles exhibit superior antimicrobial and anti-biofilm activities compared with free flavonoids, suggesting strong potential as an effective therapeutic strategy against multidrug-resistant P. aeruginosa.